BioCAPTURE publications

Scientific publications that are (partly) created with data from the BioCAPTURE research are shown here. Annually, we also prepare a report summarizing all BioCAPTURE data, this document is not freely available. You can contact us for more information on the annual report.

Risk of candidiasis associated with interleukin-17 inhibitors: A real-world observational study of multiple independent sources.Davidson L, van den Reek JMPA, Bruno M, van Hunsel F, Herings RMC, Matzaraki V, Boahen CK, Kumar V, Groenewoud HMM, van de Veerdonk FL, Netea MG, de Jong EMGJ, Kullberg BJ.Lancet Reg Health Eur. 2021 Nov 22;13:100266. doi: 10.1016/j.lanepe.2021.100266. eCollection 2022 Feb.PMID: 34950923 

Evaluation of a One-step Dose Reduction Strategy of Adalimumab, Etanercept and Ustekinumab in Patients with Psoriasis in Daily Practice. Atalay S, van der Schoot LS, Vandermaesen L, van Vugt LJ, Eilander M, van den Reek JMPA, de Jong EMGJ.Acta Derm Venereol. 2021 May 25;101(5):adv00463. doi: 10.2340/00015555-3815.PMID: 33903920.

Unmet Personal Patient Needs in Psoriasis Patients with Low Disease Activity on Adalimumab, Etanercept or Ustekinumab. van Muijen ME, Atalay S, van Vugt LJ, Vandermaesen LMD, van den Reek JMPA, de Jong EMGJ.Drugs Real World Outcomes. 2021 Jun;8(2):163-172. doi: 10.1007/s40801-021-00227-w. Epub 2021 Mar 28.PMID: 33778926 

Immunomodulatory aged neutrophils are augmented in blood and skin of psoriasis patients.Rodriguez-Rosales YA, Langereis JD, Gorris MAJ, van den Reek JMPA, Fasse E, Netea MG, de Vries IJM, Gomez-Muñoz L, van Cranenbroek B, Körber A, Sonderman W, Joosten I, de Jong EMGJ, Koenen HJPM.J Allergy Clin Immunol. 2021 Mar 19:S0091-6749(21)00418-8. doi: 10.1016/j.jaci.2021.02.041. Online ahead of print.

The Skin May Clear But the Arthritis Won’t Dissapear: Focusing on Concomitant and New-Onset Psoriatic Arthritis in a Daily Practice Cohort of Psoriasis Patients on Biologic Therapy. van Muijen ME, van Hal TW, Groenewoud HMM, van den Reek JMPA, de Jong EMGJ. Psoriasis (Auckl). 2020. Oct 5; 10:29-37. doi: 10.2147/PTT.S70619. eCollection 2020.

Clinical consequences of antibody formation, serum concentrations and HLA-Cw6 status in psoriasis patients on ustekinumab. De Keyser E, Busard CI, Lanssens S, Meuleman L, Costanzo A, van den Reek JM, Zweegers J, Lambert J, Spuls PI. Ther Drug Monit. 2019 May 16. doi: 10.1097/FTD.0000000000000646. [Epub ahead of print]

Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts. van Vugt LJ, van den Reek JMPA, Meulewaeter E, Hakobjan M, Heddes N, Traks T, Kingo K, Galluzzo M, Talamonti M, Lambert J, Coenen MJH, de Jong EMGJ. J Eur Acad Dermatol Venereol. 2019 Jul 9. doi: 10.1111/jdv.15787. [Epub ahead of print]

Female patients are less satisfied with biological treatment for psoriasis and experience more side-effects than male patients: results from the prospective BioCAPTURE registry.
van der Schoot LS, van den Reek JMPA, Groenewoud JMM, Otero ME, Njoo MD, Ossenkoppele PM, Mommers JM, Koetsier MIA, Berends MAM, Arnold WP, Peters B, Andriessen MPM, Den Hengst CW, Kuijpers ALA, de Jong EMGJ. J Eur Acad Dermatol Venereol. 2019 Jun 8. doi: 10.1111/jdv.15733. [Epub ahead of print]

Beliefs About Medicines in Patients with Psoriasis Treated with Methotrexate or Biologics: A Cross-sectional Survey Study. Otero ME, van den Reek JMPA, van de Kerkhof PCM, Mertens JS, Seyger MMB, Kievit W, de Jong EMGJ. Acta Derm Venereol. 2018 Dec 13. doi: 10.2340/00015555-3108.

Initial Results of Secukinumab Drug Survival in Patients with Psoriasis: A Multicentre Daily Practice Cohort Study. van den Reek JMPA1, van Vugt LJ, van Doorn MBA, van der Kraaij GE, de Kort WJA, Lucker GPH, Horvath B, Njoo MD, Bovenschen HJ, Ossenkoppele PM, De Bruin-Weller MS, de Groot M, Mommers R, Prevoo RLMA, van de Kerkhof PCM, Spuls PI, Kievit W, de Jong EMGJ. Acta Derm Venereol. 2018 Jul 11;98(7):648-654. doi: 10.2340/00015555-2900.

Role of the HLA-C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients.
Talamonti M, Galluzzo M, van den Reek JM, de Jong EM, Lambert JLW, Malagoli P, Bianchi L, Costanzo A. Br J Dermatol. 2017 Aug;177(2):489-496. doi: 10.1111/bjd.15387. Epub 2017 Jun 22.

Biologic treatment sequences for plaque psoriasis: a cost-utility analysis based on 10 years of Dutch real-world evidence from BioCAPTURE. Klijn SL, van den Reek JMPA, van de Wetering G, van der Kolk A, de Jong EMGJ, Kievit W. Br J Dermatol. 2017 Dec 16. doi: 10.1111/bjd.16247. Epub 2018 Mar 1.

Comment on “Drug survival analysis is not a good method for assessing the safety or effectiveness of systemic therapies in psoriasis”.  van den Reek JMPA, Kievit W, De Jong EMGJ. Actas Dermosifiliogr. 2017 Sep;108(7):695-696. doi: 10.1016/j.ad.2017.03.012. Epub 2017 May 11.

The journey of adult psoriasis patients towards biologics: past and present – Results from the BioCAPTURE registry. van den Reek JMPA, Seyger MMB, van Lümig PPM, Driessen RJB, Schalkwijk CJM, Berends MAM, van de Kerkhof PCM, de Jong EMGJ. J Eur Acad Dermatol Venereol. 2017 Nov 9. doi: 10.1111/jdv.14684.

Determinants for drug survival of methotrexate in patients with psoriasis, split according to different reasons for discontinuation: results of the prospective MTX-CAPTURE. Otero ME, van den Reek JM, Seyger MM, van de Kerkhof PC, Kievit W, de Jong EM. Br J Dermatol. 2017 Aug;177(2):497-504. doi: 10.1111/bjd.15305. Epub 2017 May 11.

Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry. Zweegers J, van den Reek JM, van de Kerkhof PC, Otero ME, Kuijpers AL, Koetsier MI, Arnold WP, Berends MA, Weppner-Parren L, Ossenkoppele PM, Njoo MD, Mommers JM, van Lümig PP, Driessen RJ, Kievit W, de Jong EM. Br J Dermatol. 2016 Aug;175(2):340-7. doi: 10.1111/bjd.14552.

Effectiveness of Biologic and Conventional Systemic Therapies in adults with Chronic Plaque Psoriasis in Daily Practice: a Systematic Review. Zweegers J, Otero ME, van den Reek JM, van Lümig PP, Driessen RJ, Kievit W, Seyger MM, van de Kerkhof PC, de Jong EM. Acta Derm Venereol. 2016 May; 96(5):453-8.

Frequency and predictors of a high clinical response in patients with psoriasis on biological therapy in daily practice: results from the prospective, multicenter BioCAPTURE cohort. Zweegers J, Roosenboom B, van de Kerkhof PC, van den Reek JM, Otero ME, Atalay S, Kuijpers AL, Koetsier MI, Arnold WP, Berends MA, Weppner-Parren L, Bijen M, Njoo MD, Mommers JM, van Lümig PP, Driessen RJ, Kievit W, de Jong EM.

Drug survival studies in Dermatology: Principles, purposes and pitfalls. Van den Reek J, Kievit M, Gniadecki R, Goeman JJ, Zweegers J, van de Kerkhof PC, Seyger MM, de Jong EM. J Invest Dermatol. 2015.Jyl; 135(7):e34.

Polymorphisms in CD84, IL12B and TNFAIP3 are associated with response to biologics in patients with psoriasis. van den Reek JM, Coenen MJ, van de L’Isle Arias M, Zweegers J, Rodijk-Olthuis D, Schalkwijk J, Vermeulen SH, Joosten I, van de Kerkhof PC, Seyger MM, Zeeuwen PL, de Jong EM. Br J Dermatol. 2017 May;176(5):1288-1296. doi: 10.1111/bjd.15005. Epub 2017 Apr 10.

Comment on “Review of patient registries in dermatology”. Zweegers J, Bronckers IM, van den Reek JM, van Geel MJ, van de Kerkhof PC, Seyger MM, de Jong EM. J Am Acad Dermatol. 2016 Dec;75(6):e241. doi: 10.1016/j.jaad.2016.05.051.

Comparison of the one and 5-years effectiveness of adalimumab, etanercept and ustekinumab in psoriasis patients in daily clinical practice. Results from the prospective BioCAPTURE registry. J. Zweegers, H. Groenewoud, J.M.P.A. van den Reek, M.E. Otero, P.C.M. van de Kerkhof, R.J.B. Driessen, P.P.M. van Lümig, M.D. Njoo, P.M. Ossenkoppele, J.M. Mommers, M.I.A. Koetsier, W.P. Arnold, M.P.M. Andriessen, A.L.A. Kuijpers, M. Berends, W. Kievit, E.M.G.J. de Jong. Br J Dermatol. 2016 Aug 31. doi: 10.1111/bjd.15023. [Epub ahead of print]

The correlation of clinical efficacy, serum trough levels and antidrug antibodies in ustekinumab-treated patients with psoriasis in a clinical-practice setting. Menting SP, van den Reek JM, Baerveldt EM, de Jong EM, Prens EP, Lecluse LL, Wolbink GJ, Van der Kleij D, Spuls PI, Rispens T. Br J Dermatol. 2015 Sep;173(3):855-7. doi: 10.1111/bjd.13834. Epub 2015 Aug 2.

Adalimumab drug survival in patients with Psoriasis, Crohn’s disease, and Rheumatoid Arthritis: relevant differences using the same treatment.
Pijls P.A.R.R., van den Reek J.M.P.A.,. de Jong E.M.G.J,. Tummers M., van Riel P.C.L.M., Kievit W., Hoentjen F. J Am Acad Dermatol. 2016 Jan;74(1):177-9. doi: 10.1016/j.jaad.2015.08.010.

Developing a Therapeutic Range of Adalimumab Serum Concentrations in Management of Psoriasis: A Step Toward Personalized Treatment. Menting S.P., van den Reek JMPA et al. JAMA Dermatol. 2015 Jun;151(6):616-22. doi: 10.1001/jamadermatol.2014.5479.

Predictors of adalimumab drug-survival in psoriasis differ by reasons for discontinuation. Long term results from a prospective daily-practice cohort. Van den Reek JMPA, Tummers M, Zweegers J, Seyger MMB, van Lümig PPM, Driessen RJB, van de Kerkhof PCM, Kievit W,de Jong EMGJ.J Eur Acad Dermatol Venereol. 2015 Mar;29(3):560-5. doi: 10.1111/jdv.12636. Epub 2014 Aug 4.

Extent and consequences of antibody formation against adalimumab in patients with psoriasis: one-year follow-up. Menting, S.P., Van Lümig PP, de Vries AC, van den Reek JM, vander Kleij D, de Jong EM, Spuls PI, Lecluse LL. JAMA Dermatol, 2014. 150(2): p. 130-6

An increased risk of non-melanoma skin cancer during TNF-inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease-related factors. Van Lumig PPM, Menting S, van den Reek JMPA, Spuls Ph.I., van Riel PL, van de Kerkhof PCM, Fransen J, Kievit W, de Jong EMGJ. J Eur Acad Dermatol Venereol. 2014 Sep 17. doi: 10.1111/jdv.12675.

Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis.
Lecluse LL, Driessen RJ, Spuls PI, de Jong EM, Stapel SO, van Doorn MB, Bos JD, Wolbink GJ. Arch Dermatol, 2010. 146(2): p. 127-32.

Comparing treatment goals for psoriasis to treatment decisions in daily practice. Results from a prospective cohort of psoriasis patients treated with biologics: Bio-Capture. J. Zweegers, J.M.P.A. van den Reek, M.E. Otero, PM Ossenkoppele, MD Njoo, JM Mommers, MIA Koetsier, WP Arnold, BAM Sybrandy-Fleuren, ALA Kuijpers, MPM Andriessen, P.C.M. van de Kerkhof, W. Kievit, E.M.G.J. de Jong. Br J Dermatol. 2014 Nov;171(5):1091-8. doi: 10.1111/bjd.13137. Epub 2014 Oct 20.

Happy Drug Survival of Adalimumab, Etanercept and Ustekinumab in Psoriasis in Daily Practice Care. Results from the BioCAPTURE network. JMPA van den Reek, J Zweegers, W Kievit,ME Otero, PPM van Lümig, RJB Driessen, PM Ossenkoppele, MD Njoo, JM Mommers, MIA Koetsier, WP Arnold, BAM Sybrandy-Fleuren, ALA Kuijpers, MPM Andriessen, PCM van de Kerkhof, MMB Seyger, EMGJ de Jong. Br J Dermatol. 2014 Nov;171(5):1189-96. doi: 10.1111/bjd.13087. Epub 2014 Oct 3.

Satisfaction with medication is high for biologics in psoriasis. Results from the BioCAPTURE network. Van den Reek JMPA, PPM van Lümig, ME Otero, J Zweegers, PCM van de Kerkhof, PM Ossenkoppele, MD Njoo, JM Mommers, MIA Koetsier, WP Arnold, BAM Sybrandy, ALA Kuijpers, MPM Andriessen, MMB Seyger, W Kievit,EMGJ de Jong. Br J Dermatol. 2014 May;170(5):1158-65.

Determinants of drug survival for etanercept in a long-term daily practice cohort of patients with psoriasis. Van den Reek JMPA, van Lümig PPM, Driessen RJB, van de Kerkhof PCM, Seyger MMB, Kievit W,de Jong EMGJ. Br J Dermatol. 2014 Feb;170(2):415-24.

Effectiveness of adalimumab dose escalation, combination of adalimumab and methotrexate, or both in patients with psoriasis in daily practice. Van den Reek JMPA, van Lümig PPM, Kievit W, Zweegers J, van de Kerkhof PCM, Seyger MMB, de Jong EMGJ. J Dermatolog Treat. 2013 Oct;24(5):361-8.

Results of three analytical approaches on long-term efficacy of etanercept for psoriasis in daily practice. Van Lumig PPM, Driessen RJB, Boezeman JBM, van de Kerkhof PCM, de Jong EMGJ. J Am Acad Dermatol J Am Acad Dermatol. 2013;68:57-63

Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naive versus non-naive patients. Van Lumig PPM, van de Kerkhof PCM, Boezeman JBM, Driessen RJB, de Jong EMGJ. J Eur Acad Dermatol Venereol. 2013 May;27(5):593-600.

Long-term efficacy of etanercept for psoriasis in daily practice. Van Lumig PPM, Driessen RJB, Boezeman JBM, van de Kerkhof PCM, de Jong EMGJ. Br J Dermatol 2012 Feb;166(2):445-7.

Safety of treatment with biologics for psoriasis in daily practice: 5-year data. Van Lumig PPM, Driessen RJB, van de Kerkhof PCM, de Jong EMGJ. J Eur Acad Dermatol Venereol 2012 Mar;26(3):283-91.

Switching from etanercept to adalimumab is effective and safe. Results in 30 psoriasis patients with primary failure, secondary failure or intolerance to etanercept. Van Lumig PPM, Lecluse LL, Driessen RJB, Spuls PI, Boezeman JB, van de Kerkhof PCM, de Jong EMGJ. Br J Dermatol. 2010 Oct;163(4):838-46.

The economic impact of high-need psoriasis in daily clinical practice before and after the introduction of biologics. Driessen RJB, Bisschops LA, Adang EM, Evers AW, van de Kerkhof PCM, de Jong EMGJ. Br J Dermatol. 2010 Jun;162(6):1324-9.

Daily practice assessment of liver injury in patients with psoriasis on methotrexate. Driessen RJB, van de Kerkhof PCM, de Jong EMGJ. Br J Dermatol 2010 Jan;162(1):211-3.

Three-year registry data on biological treatment for psoriasis: the influence of patiënt characteristics on treatment outcome. Driessen RJB, Boezeman JB, van de Kerkhof PCM, de Jong EMGJ. Br J Dermatol. 2009 Mar;160(3):670-5.

Cardiovascular risk factors in high-need psoriasis patients and its implications for biological therapies. Driessen RJB, Boezeman JB, van de Kerkhof PCM, de Jong EMGJ. J Dermatolog Treat. 2008 Jul 21:1-5.

Analysis of three-year national reimbursement application data of etanercept and efalizumab for psoriasis. Driessen RJB, de Jong EMGJ, Salemink G, de Rie MA, van de Kerkhof PCM. Br J Dermatol. 2008 Sep;159(3):760-1.

Etanercept combined with methotrexate for high need psoriasis. Driessen RJB, van de Kerkhof PCM, de Jong EMGJ. Br J Dermatol. 2008 Aug;159(2):460-3.

Psoriasis treatment with etanercept and efalizumab: clinical strategies influencing treatment outcome. Driessen RJB, Berends MAM, Boezeman JB, van de Kerkhof PCM, de Jong EMGJ. Br J Dermatol. 2008 May;158(5):1098-106.

Etanercept and efalizumab treatment for high need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice. Berends MAM, Driessen RJB, Langewouters AMG, Boezeman JB, van de Kerkhof PCM, de Jong EMGJ. J Dermatol Treat 2007;18:76-83